<DOC>
	<DOCNO>NCT00674024</DOCNO>
	<brief_summary>Background : - Pazopanib experimental drug design enter cancer cell block activity protein important cancer cell growth survival . - This first study pazopanib give patient different degree liver function . The safe dose patient normal liver function already know . Objectives : - To determine safety side effect pazopanib give different dose level patient cancer different degree liver function . - To find much pazopanib blood specific time . - To determine pazopanib effective treating advance cancer patient different degree liver function . Eligibility : - Patients 18 year age old advance solid tumor lymphoma treat successfully standard therapy normal abnormal liver function . Design : - Treatment : - Patients divide 4 group , base liver function . The first three patient group receive low dose pazopanib . The next three group receive high dose pazopanib serious side effect report previous three . The dose increase succeed group three patient maximum study dose reach . - Patients take pazopanib day mouth 21-day treatment cycle . Treatment continue cancer worsens , patient develops severe side effect , patient longer want continue study , doctor remove patient study reason . - Monitoring : - Blood pressure : Patients monitor record blood pressure twice day start treatment . - Blood test : Patients weekly routine blood test . In addition , week 3 first cycle high safe dose determine , several blood sample collect frequent interval determine body handle drug . - Imaging study : X-rays scan do measure extent disease every 3 cycle . - Physical examination do periodic interval .</brief_summary>
	<brief_title>Pazopanib Treat Adults With Advanced Cancers Varying Degrees Liver Function</brief_title>
	<detailed_description>Background : - Pazopanib potent , multi-targeted receptor tyrosine kinase inhibitor VEGFR-1 , VEGFR-2 , VEGFR-3 , PDGFR-alpha , PDGFR-beta , c-kit potential inhibit angiogenesis , lymphangiogenesis , tumor growth may advantage agent narrow kinase specificity profile . - Pazopanib show activity renal cell cancer tumor shrinkage stable disease ; Phase I , II , III trial single therapy combination lapatinib ongoing planned patient various solid tumor . - Pazopanib appear well tolerate dose 50 mg three time weekly 2000 mg daily ; common adverse event hypertension , diarrhea , nausea , fatigue , hair depigmentation . Objectives : - To establish maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) pazopanib group patient vary degree hepatic dysfunction ( mild , moderate , severe ) order provide appropriate dosing recommendation pazopanib patient . - To characterize pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile pazopanib metabolite ( GSK1071306 , GSK1268992 , GSK1268997 , GW700201 ) patient vary degree hepatic dysfunction . - To document non-DLTs associate administration pazopanib patient hepatic dysfunction . - To explore correlation Child-Pugh classification hepatic dysfunction observe toxicity , plasma PK , PD pazopanib administration . - To document antitumor activity associate pazopanib treatment patient enrol study . Eligibility : - Adult patient must histologically cytologically confirm solid tumor lymphoma metastatic unresectable standard curative palliative measure exist longer effective . - Patients must adequate renal bone marrow function . Study Design : - Patients stratify four cohort accord hepatic function . - Pazopanib administer orally daily day 1-21 21-day cycle . - Blood sample PK collect patient . - A minimum 2 maximum 12 patient accrue liver dysfunction group dose , 12 patient enter recommended dose level group . At least 12 patient accrue normal liver function group . The estimated maximum accrual 132 patient , include center .</detailed_description>
	<criteria>INCLUSION CRITERIA : For patient NCI , histological cytological confirmation solid tumor lymphoma diagnosis perform NCI Laboratory Pathology . EXCLUSION CRITERIA : Patients prior treatment pazopanib eligible study . Patients abnormal liver function except grade 4 AST , grade 4 ALT , grade 4 bilirubin eligible group accord criterion Section 5.1 . For assess hepatic dysfunction , great 35 percent total bilirubin must direct bilirubin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>January 22, 2013</verification_date>
	<keyword>Pazopanib</keyword>
	<keyword>Tyrosine Kinase Inhibitor</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Lymphoma</keyword>
</DOC>